HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
Table 2
Characteristics of patients with HER2+ breast cancer receiving neoadjuvant chemotherapy: evaluation of residual cancer burden in 151 patients.
Total
RCB-0 ()
RCB-I ()
RCB-II ()
RCB-III ()
values
Mean (SE)
Mean
SE
Mean
SE
Mean
SE
Mean
SE
Age
52.9 (11.8)
54.1
11.7
52.0
11.5
50.9
11.7
57.5
14.6
0.4700
Pretreatment tumor size
3.6 (2.3)
3.3
2.1
3.4
2.0
3.7
2.2
6.2
4.1
0.0517†
%
%
%
%
Pretreatment clinical stage
Na
1
18
12
18.8%
4
12.5%
2
4.3%
0
0.0%
2
91
39
60.9%
18
56.3%
30
63.8%
4
50.0%
3
42
13
20.3%
10
31.3%
15
31.9%
4
50.0%
Tumor type
Na
IDC
134
59
92.2%
29
90.6%
40
85.1%
6
75.0%
Micropapillary
11
4
6.3%
2
6.3%
3
6.4%
2
25.0%
Mucinous
1
0
0.0%
0
0.0%
1
2.1%
0
0.0%
Apocrine
1
0
0.0%
0
0.0%
1
2.1%
0
0.0%
ILC
3
1
1.6%
1
3.1%
1
2.1%
0
0.0%
Mixed IDC-ILC
1
0
0.0%
0
0.0%
1
2.1%
0
0.0%
Na
13
7
10.9%
2
6.3%
4
8.5%
0
0.0%
Tumor grade
Na
I
1
0
0.0%
0
0.0%
1
2.1%
0
0.0%
II
54
20
31.3%
13
40.6%
17
36.2%
4
50.0%
III
96
44
68.8%
19
59.4%
29
61.7%
4
50.0%
ER status
0.0027‡
Positive (10-100%)
88
28
43.8%
22
68.8%
31
66.0%
7
87.5%
Negative (<10%)
63
36
56.3%
10
31.3%
16
34.0%
1
12.5%
PgR status
0.3776
Positive (10-100%)
55
21
32.8%
11
34.4%
18
38.3%
5
62.5%
Negative (<10%)
96
43
67.2%
21
65.6%
29
61.7%
3
37.5%
Hormone sensitive (ER or PgR+)
0.02‡
Yes (10-100%)
89
29
45.3%
22
68.8%
31
66.0%
7
87.5%
No (<10%)
62
35
54.7%
10
31.3%
16
34.0%
1
12.5%
Multiple tumors on imaging (pretreatment)
<0.0001‡
Yes
22
1
1.6%
7
21.9%
10
21.3%
4
50.0%
No
129
63
98.4%
25
78.1%
37
78.7%
4
50.0%
Continuous variable values are calculated using the Kruskal-Wallis test, and values for the categorical variables are calculated using the Chi square or Fisher’s exact test. †Marginally significant. ‡Statistically significant.
